Surmodics
SRDX
Market cap $401M

28.04 USD

-2.89

9.34%

Updated Apr 30, 3:59 PM EDT

1 day

-9.34%

5 days

-1.79%

1 month

-8.16%

3 months

-20.97%

6 months

-25.23%

Year to date

-29.33%

1 year

9.15%

5 years

-26.40%

10 years

11.18%

About: Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Employees: 389

Healthcare Medical Devices

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 12

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

95% more call options, than puts

Call options by funds: $1.33M | Put options by funds: $681K

15% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 39

10% more funds holding

Funds holding: 126 [Q3] → 138 (+12) [Q4]

1.09% more ownership

Funds ownership: 83.17% [Q3] → 84.26% (+1.09%) [Q4]

4% more capital invested

Capital invested by funds: $457M [Q3] → $476M (+$19.2M) [Q4]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$43

53%

upside

Avg. target

$43

53%

upside

High target

$43

53%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Lake Street

Brooks O'Neil

44% 1-year accuracy

7 / 16 met price target

53%upside

$43

Buy

Upgraded

7 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about SRDX published over the past 30 days

Zacks Investment Research

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.

SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (.

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments.

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were.

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Zacks Investment Research

SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System

Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.

SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10 mm in diameter,.

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Zacks Investment Research

Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.

Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

Zacks Investment Research

SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge

The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.

SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”), which have an equity investment in Biocoat Inc., a maker of medical coatings: “Surmodics.

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

See News Rankings

Charts implemented using Lightweight Charts™